Fedele Monica, Fusco Alfredo
Istituto di Endocrinologia ed Oncologia Sperimentale del CNR c/o Dipartimento di Biologia e Patologia Cellulare e Molecolare Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, Facoltà di Medicina e Chirurgia di Napoli, Università degli Studi di Napoli "Federico II", via Pansini 5, 80131 Naples, Italy.
Biochim Biophys Acta. 2010 Jan-Feb;1799(1-2):48-54. doi: 10.1016/j.bbagrm.2009.11.007.
Long-standing studies have clearly established that the architectural chromatinic proteins High Mobility Group A (HMGA) are among the most widely expressed cancer-associated proteins. Indeed, their overexpression represents a constant feature of human malignancies, and correlates with a poor prognosis. Moreover, HMGA dysregulation, as a result of specific chromosomal rearrangements, occurs in a broad variety of common benign mesenchymal tumors, making HMGA genes among the most commonly rearranged genes in human neoplasms. Nevertheless, recent data propose a critical role of HMGA overexpression also in the generation of pituitary adenomas. Here, we review the involvement of HMGA proteins in cancer, analyzing the mechanisms underlying their crucial role in tumorigenesis, and, finally, discuss the potentiality of a cancer treatment based on HMGA targeting.
长期以来的研究已明确证实，架构染色质蛋白高迁移率族A（HMGA）是表达最为广泛的癌症相关蛋白之一。事实上，它们的过表达是人类恶性肿瘤的一个持续特征，且与预后不良相关。此外，由于特定的染色体重排导致的HMGA失调，发生在多种常见的良性间叶肿瘤中，使得HMGA基因成为人类肿瘤中最常发生重排的基因之一。然而，最近的数据表明HMGA过表达在垂体腺瘤的发生中也起关键作用。在此，我们综述HMGA蛋白在癌症中的作用，分析其在肿瘤发生中发挥关键作用的潜在机制，最后讨论基于靶向HMGA的癌症治疗的潜力。
